Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens

Background: With the introduction of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy, persons living with HIV have a potent new treatment option. Recently, providers at our large treatment clinic noted weight gain in several patients who switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). In this study, we evaluated weight change in patients with sustained virologic suppression who switched from EFV/TDF/FTC to an INSTI-containing regimen. Methods: We performed a retrospective observational cohort study among adults on EFV/TDF/FTC for at least 2 years who had virologic suppression. We assessed weight change over 18 months in patients who switched from EFV/TDF/FTC to an INSTI-containing regimen or a protease inhibitor (PI)-containing regimen versus those on EFV/TDF/FTC over the same period. In a subgroup analysis, we compared patients switched to DTG/ABC/3TC versus raltegravir- or elvitegravir-containing regimens. Results: A total of 495 patients were included: 136 who switched from EFV/TDF/FTC to an INSTI-containing regimen and 34 switched to a PI-containing regimen. Patients switched to an INSTI-containing regimen gained an average of 2.9 kg at 18 months compared with 0.9 kg among those continued on EFV/TDF/FTC (P = 0.003), whereas those switched to a PI regimen gained 0.7 kg (P = 0.81). Among INSTI regimens, those switched to DTG/ABC/3TC gained the most weight at 18 months (5.3 kg, P = 0.001 compared with EFV/TDF/FTC). Conclusion: Adults living with HIV with viral suppression gained significantly more weight after switching from daily, fixed-dose EFV/TDF/FTC to an INSTI-based regimen compared with those remaining on EFV/TDF/FTC. This weight gain was greatest among patients switching to DTG/ABC/3TC.

[1]  P. Korthuis,et al.  Integrase strand transfer inhibitor-associated diabetes mellitus: A case report , 2017, International journal of STD & AIDS.

[2]  Kathleen M. Akgün,et al.  Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals , 2016, Journal of Acquired Immune Deficiency Syndromes.

[3]  C. Fletcher,et al.  Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors , 2016, Clinical Pharmacokinetics.

[4]  Richard D Moore,et al.  Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. , 2016, AIDS research and human retroviruses.

[5]  Roopali Sharma,et al.  Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection , 2015, Expert review of anti-infective therapy.

[6]  D. Leaf,et al.  Weight change after antiretroviral therapy and mortality. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Kuritzkes,et al.  Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  I. Grant,et al.  Abdominal Obesity Contributes to Neurocognitive Impairment in HIV-Infected Patients With Increased Inflammation and Immune Activation , 2015, Journal of acquired immune deficiency syndromes.

[9]  B. Clotet,et al.  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study , 2014, The Lancet.

[10]  S. Walmsley,et al.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.

[11]  P. Cahn,et al.  Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study , 2013, The Lancet.

[12]  Clare Brennan,et al.  Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study , 2013, The Lancet.

[13]  S. Chow,et al.  Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. , 2013, AIDS research and human retroviruses.

[14]  J. Gathe,et al.  Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. , 2012, AIDS research and human retroviruses.

[15]  A. Westfall,et al.  Multimorbidity Patterns in HIV-Infected Patients: The Role of Obesity in Chronic Disease Clustering , 2012, Journal of acquired immune deficiency syndromes.

[16]  Tyler H Tate,et al.  HIV Infection and Obesity: Where Did All the Wasting Go? , 2012, Antiviral therapy.

[17]  C. Katlama,et al.  Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment , 2012, AIDS.

[18]  A. Lazzarin,et al.  Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  B. Chi,et al.  Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in Urban Zambia , 2010, AIDS.

[20]  L. Eberly,et al.  Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic , 2010, PloS one.

[21]  B. Chi,et al.  Association Between Weight Gain and Clinical Outcomes Among Malnourished Adults Initiating Antiretroviral Therapy in Lusaka, Zambia , 2010, Journal of acquired immune deficiency syndromes.

[22]  L. Ferradini,et al.  Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries. , 2009, AIDS.

[23]  S. Crystal,et al.  HIV infection and the risk of diabetes mellitus , 2008, AIDS.

[24]  J. Gallant.  Making sense of blips. , 2007, The Journal of infectious diseases.

[25]  A. Earnest,et al.  The impact of malnutrition on survival and the CD4 count response in HIV‐infected patients starting antiretroviral therapy , 2006, HIV Medicine.

[26]  W. Beisel,et al.  Metabolic effects of infection on protein and energy status. , 2003, The Journal of nutrition.

[27]  Juan Macías,et al.  Transient Rebounds of Low-Level Viraemia among HIV-Infected Patients under Haart are Not Associated with Virological or Immunological Failure , 2001, Antiviral therapy.

[28]  D. Spiegelman,et al.  Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. , 1999, AIDS.

[29]  J. Crowley,et al.  Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. , 1998, The American journal of physiology.

[30]  S A Jebb,et al.  Energy expenditure and wasting in human immunodeficiency virus infection. , 1995, The New England journal of medicine.

[31]  M. McNurlan,et al.  Whole-body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. , 1995, The American journal of clinical nutrition.

[32]  E. Casalino,et al.  Resting energy expenditure in human immunodeficiency virus-infected patients: comparison between patients with and without secondary infections. , 1993, The American journal of clinical nutrition.

[33]  K. Feingold,et al.  Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The American journal of clinical nutrition.

[34]  C. Leport,et al.  Resting energy expenditure is increased in stable, malnourished HIV-infected patients. , 1991, The American journal of clinical nutrition.